This article will focus on pulmonary hypertension, or, more specifically, pulmonary arterial hypertension (PAH), and will review clinical findings associated with the disease as well as diagnostic ...

Although some cases of PAH have known causes, such as genetic factors, many cases have no identifiable underlying cause and are designated as idiopathic. Early diagnosis and treatment are critical for ...

Researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation ...

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, and welcome to this podcast series. I'm Dr Vallerie McLaughlin, the Kim A. Eagle Endowed Professor of Cardiovascular ...

New data reported in a presentation at the American College of Rheumatology (ACR) annual meeting showed that tumor necrosis factor (TNF) receptor 1 (TNFR1) rather than TNFR2 is responsible for ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.